BackTakeda Pharmaceutical Company Limited Overview

Takeda Pharmaceutical Company Limited EBIT

Track Takeda Pharmaceutical Company Limited's EBIT ($760B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$219.35B
↑ 97.06% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$755.59B
↑ 106.08% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Takeda Pharmaceutical Company Limited (TKPHF) FAQ

As of the most recent data (September 2026), TKPHF shows a EBIT of $760B. That compares with $370B in the prior-year period — up 106.1% year over year. That is below the Healthcare sector average of $1.9T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TKPHF's EBIT is now $760B (was $370B) — a 106.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Takeda Pharmaceutical Company Limited is outperforming or lagging.

The Healthcare sector average EBIT is about $1.9T. Takeda Pharmaceutical Company Limited is at $760B, which is lower that average. That is roughly 61.1% below the sector mean. Use the comparison chart on this page to see how TKPHF stacks up against individual peers as well.

Tracking TKPHF's ebit over time shows whether Takeda Pharmaceutical Company Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $760B That compares with $370B in the prior-year period — up 106.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Takeda Pharmaceutical Company Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $760B) with ownership activity and broader fundamentals.